What is the local treatment for eye discharge during radiation therapy (RT) of basal cell carcinoma (BCC) of the eyelid skin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For eye discharge during radiation therapy of basal cell carcinoma of the eyelid skin, the recommended local treatment is gentle cleansing with sterile saline solution or mild, preservative-free artificial tears, followed by the application of antibiotic ophthalmic ointments such as erythromycin or bacitracin. This approach is based on general principles of managing ocular surface inflammation and preventing secondary bacterial infections that can occur during radiation therapy, as radiation can damage the meibomian glands and lacrimal apparatus, reducing tear production and disrupting the protective tear film 1. Key points to consider in the management include:

  • Cleaning the affected eye 2-3 times daily by wiping from the inner to outer corner with a clean, damp cloth.
  • For moderate to severe discharge, tobramycin 0.3% or ciprofloxacin 0.3% ophthalmic drops may be prescribed, typically 1-2 drops 3-4 times daily for 7-10 days.
  • Preservative-free lubricating eye drops can also help manage dryness and irritation, applied 4-6 times daily as needed. Patients should avoid rubbing the eyes and should report worsening symptoms, vision changes, or severe pain immediately as these may indicate more serious complications requiring additional intervention. While the provided evidence primarily focuses on the management of basal cell carcinoma and radiation dermatitis, the principles of gentle cleansing, use of antibiotic ointments, and lubricating eye drops are broadly applicable to managing eye discharge during radiation therapy, prioritizing the prevention of infection and the maintenance of ocular surface health 1.

From the FDA Drug Label

One drop instilled into the affected eye(s) four times daily. Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2-0. 5%) in clinical studies included ... discharge

The local treatment for eye discharge during radiation therapy of basal cell carcinoma of the eyelid skin is loteprednol etabonate ophthalmic suspension, with a dosage of one drop instilled into the affected eye(s) four times daily 2.

  • Key points:
    • Dosage: one drop four times daily
    • Medication: loteprednol etabonate ophthalmic suspension
    • Reference: 2

From the Research

Local Treatment for Eye Discharge during RT of BCC of the Eyelid Skin

  • The local treatment for eye discharge during radiation therapy (RT) of basal cell carcinoma (BCC) of the eyelid skin is not explicitly mentioned in the provided studies 3, 4, 5, 6, 7.
  • However, the studies suggest that radiation therapy is a safe and effective treatment for BCC of the eyelid skin, with good tumor control and minimal side effects 3, 5.
  • Electrochemotherapy (ECT) has also been shown to be effective in the treatment of locally advanced or recurrent BCC of the eyelid-periocular skin region, with excellent tumor control and good functional and cosmetic results 4.
  • Immunotherapy, including topical therapies such as imiquimod, has been used in the management of BCC, but its efficacy in the treatment of eye discharge during RT is not established 6.
  • The optimal therapy for BCC of the eyelid and periocular skin is controversial, and treatment strategy is formulated on an individual basis, taking into account tumor size, anatomic location, and growth pattern 7.

Management of Side Effects

  • Radiation-induced cataracts and lower eyelid ectropion are potential side effects of RT and ECT, respectively 3, 4.
  • The management of these side effects is crucial to minimize their impact on the patient's quality of life.
  • Further research is needed to establish the most effective local treatment for eye discharge during RT of BCC of the eyelid skin.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2012

Research

Basal and squamous cell carcinoma of the eyelids and their treatment by radiotherapy.

International journal of radiation oncology, biology, physics, 1984

Research

Immunotherapy in Basal Cell Carcinoma.

Journal of clinical medicine, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.